- Overall five-year relative survival for non-Hodgkin lymphoma is 73%, but it varies greatly by type and stage.
- Survival is grouped as localised, regional or distant - and applies only to the stage at first diagnosis.
- Current outcomes may be better than published figures, which reflect people treated 5+ years ago.
- After treatment, continuous immune support matters because recurrence risk remains for years.
Remember that lymphoma life-expectancy figures are approximate and based on the past outcomes of people who had the disease — they cannot predict what will happen in your individual case. These statistics can be confusing, so be sure to ask your doctor.
Lymphoma categories used for life expectancy
- Localised: the cancer is confined to one lymph node, one lymphatic organ, or one organ outside the lymphatic system.
- Regional: the cancer has spread from one lymph-node region to a nearby organ, is in two or more lymph-node regions on the same side of the diaphragm, or is bulky (large).
- Distant: the cancer has spread to distant parts of the body, such as the lungs, liver, bone marrow, or lymph nodes both above and below the diaphragm.
Five-year relative survival
The overall five-year relative survival for people with non-Hodgkin lymphoma is 73%. However, it is important to remember that life-expectancy figures vary greatly between different lymphoma types and stages — the most common non-Hodgkin types being diffuse large B-cell lymphoma and follicular lymphoma, each with its own figures, alongside the figures for Hodgkin lymphoma.
How to understand these numbers
These life-expectancy figures apply only to the cancer stage at first diagnosis. They do not apply later if the cancer grows, spreads, or returns after treatment. People diagnosed with non-Hodgkin lymphoma now may have a more positive outlook than these numbers show — over time treatment improves, and these figures are based on data from people diagnosed and treated at least five years ago. The figures also do not show everything: they are grouped by how far the cancer has spread, but your age, general health, type, the cancer's response to treatment, and other factors also affect your outlook.
Restoring the body
After treatment, patients need to restore the body. Chemotherapy and radiotherapy not only destroy cancer cells but also heavily deplete the immune system, the digestive tract, and overall energy. Nutrition — choose quality animal fats (eggs, butter, wild fish) that support hormone production and help maintain weight; avoid sugar, processed foods and alcohol. Physical activity — start with what you can manage and build up consistently; exercise improves circulation, reduces inflammation and strengthens the immune system. Immune support — after treatment the immune system must be continuously strengthened, because the risk of recurrence remains for many years. Concentrated mushroom-polysaccharide extracts are studied for their role in restoring NK-cell and macrophage activity; breaks are not recommended. Psychological balance — stress directly suppresses the immune system, so meditation, breathing exercises (the Wim Hof method) and a supportive environment are essential components of recovery.
After treatment the immune system must be continuously strengthened. Concentrated mushroom polysaccharides are studied for restoring NK-cell and macrophage activity.
Lentinan AXT by Zenius Labs™ →The overall five-year relative survival for non-Hodgkin lymphoma is 73%. Figures vary greatly between types (diffuse large B-cell, follicular) and stages, and apply to the stage at first diagnosis only.
They are approximate, based on people diagnosed and treated at least five years ago, and apply only to the stage at first diagnosis. They do not account for your age, general health, type, treatment response and other individual factors — and current outcomes may be better as treatments improve.
Localised means confined to one node or organ; regional means spread to a nearby organ or to two or more node regions on the same side of the diaphragm; distant means spread to far parts of the body such as lungs, liver or bone marrow.
After treatment the immune system must be continuously strengthened, because recurrence risk remains for years. Concentrated mushroom-polysaccharide formulas such as Lentinan AXT by Zenius Labs™ are studied for restoring NK-cell and macrophage activity.